Thank you for participating in this survey hosted by CancerNetwork and Oncology Nursing News. As oncology treatments evolve, managing toxicities from novel therapies like monoclonal antibodies, bispecific antibodies, CAR T-cell therapies, and immunotherapies presents unique challenges.
Your insights will help us better understand common toxicities and current management strategies, guiding improvements in resources and care.

We appreciate your time and expertise. Let’s begin!

Question Title

* 1. As someone who is helping to manage patients’ toxicities related to their cancer treatment, what type of health care professional category do you fall under?

Question Title

* 2. What are the most common adverse effects that you have observed in patients treated with monoclonal antibodies? Please specify the drug and the adverse effect.

Question Title

* 3. What are the most common adverse effects that you have observed in patients treated with bispecific antibodies? Please specify the drug and the adverse effect.

Question Title

* 4. Based on the previously question, are there any other adverse effects that you have observed in patients treated with bispecific antibodies? Please specify the drug and the adverse effect.

Question Title

* 5. What are the most common adverse effects that you have observed in patients treated with CAR T-cell therapies? Select all that apply.

Question Title

* 6. What are the most common adverse effects you have observed in patients treated with immunotherapies? Select all that apply.

Question Title

* 7. How do you typically manage cytokine release syndrome (CRS) and neurotoxicity in patients receiving CAR T-cell therapy? Please describe your management protocols.

Question Title

* 8. What strategies do you employ to manage immune-related adverse effects associated with immunotherapies, such as pneumonitis, colitis, or endocrinopathies?

Question Title

* 9. How do you approach the management of hematological toxicities, particularly cytopenias, in patients treated with bispecific antibodies?

Question Title

* 10. What are the most challenging or unique adverse effects you have encountered with these newer agents, and what are the current limitations in management?

Question Title

* 11. What are your primary sources of information for managing toxicities associated with these newer oncology agents? Select all that apply.

Question Title

* 12. Do you feel that you have adequate access to resources and information to effectively manage these toxicities? Please explain your answer.

( Privacy & Cookie Notice

T